The Facts
Pfizer and BioNTech will run three simultaneous trials in adults ages 18-55 to determine if an Omicron-specific vaccine is more effective than current shots.
Pfizer CEO Albert Bourla said an Omicron vaccine will be ready in March, and the company is already manufacturing doses.
The Spin
Narrative A
Omicron is leading to a global surge in breakout cases. Omicron-specific vaccines are prudent and could help with future variants.
Narrative B
Vaccines and boosters are great, but Omicron is mild and spreading too quickly to be stopped. We should aim for natural herd immunity and vaccinate only the vulnerable. Resistance is futile.
